131805-94-2

Basic information

• Product Name: 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE
• Synonyms: BUTTPARK 41\03-56;3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE;3,5-BIS(TRIFLUOROMETHYL)PHENACYL BROMIDE;2-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANONE;2-BROMO-1-[3,5-DI(TRIFLUOROMETHYL)PHENYL]ETHAN-1-ONE;2-Bromo-1-[3,5-di(trifluoromethyl)phenyl]ethan-1-one, 95+%;3,5-Bis(trifluoromethyl)phenacyl bromide 97%;3,5-Bis(trifluoromethyl)phenacylbromide97%
• CAS NO: 131805-94-2
• Molecular Formula: C₁₀H₅BrF₆O
• Molecular Weight: 335.04
• Product Categories: Benzene series
• Mol File: 131805-94-2.mol

Chemical Properties

• Melting Point: 44-46
• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE(131805-94-2)
• EPA Substance Registry System: 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE(131805-94-2)

Safety Data

• Hazard Codes: Xi
• Statements: 34-36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 1760
• HazardClass: IRRITANT
• Hazardous Substances Data: 131805-94-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE is utilized as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and medicines. Its unique properties allow for the creation of complex molecular structures that can address specific medical needs.
Used in Agrochemical Production:
In the agrochemical industry, 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE serves as a key intermediate, aiding in the production of compounds that protect crops and enhance agricultural yields. Its role in this sector is crucial for developing effective and targeted agrochemicals.
Used in Organic Compounds Synthesis:
3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE is also employed as a building block in the synthesis of other organic compounds, particularly fluorinated ones. The incorporation of fluorine atoms can significantly alter the properties of organic molecules, making them more stable or reactive as required for specific applications.
Used in Research and Development:
Due to its strong electron-withdrawing properties, 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE is a valuable compound in research and development settings. It is used to explore new reaction pathways and to understand the behavior of molecules under various conditions, thus advancing the field of organic chemistry.
Safety Considerations:
It is imperative to handle 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE with care due to its potential hazards. It may be harmful if ingested, inhaled, or if it comes into contact with the skin and eyes. Proper safety measures, including the use of personal protective equipment, should be strictly adhered to during its manipulation and storage.

Upstream product

• 186581-53-3 diazomethane 
• 725-89-3 3,5-bistrifluoromethylbenzoic acid 
• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 
• 1246224-45-2 1-(bromoethynyl)-3,5-bis(trifluoromethyl)benzene 

Downstream Products

• 39031-52-2 3,5-bis-trifluoromethylphenyl-oxoacetaldehyde 
• 284665-41-4 2-[3',5'-bis(trifluoromethyl)phenyl]imidazo[1,2-a]pyridine 
• 237384-88-2 methyl 4-{4-[3,5-bis(trifluoromethyl)phenyl](1,3-thiazol-2-yl)}-5-methylthiothiophene-2-carboxylate 
• 254910-94-6 methyl 4-[4-[3,5-bis(trifluoromethyl)phenyl]-2-oxazolyl]benzoate 
• 131805-95-3 ethyl 4-(3,5-ditrifluoromethylphenyl)-2-oxazolepropionate 
• 1040744-24-8 1-(3,5-bis(trifluoromethyl)phenyl)-λ²-(triphenyl-5-phosphanylidene)ethan-1-one 
• 1214257-88-1 2-(4-(3,5-bis(trifluoromethyl)phenyl)thiazol-2-yl)-1-(3-phenylisoquinolin-1-yl)hydrazine 
• 1325205-66-0 N,N'-bis(2,6-diisopropylphenyl)-N-{2-oxo-2-[3,5-bis(trifluoromethyl)phenyl]ethyl}benzimidamide 
• 1252657-91-2 methyl 3-{4-[3,5-bis(trifluoromethyl)phenyl]-1,3-oxazol-2-yl}propanoate 
• 131837-81-5 3-{4-[3,5-bis(trifluoromethyl)phenyl]-1,3-oxazol-2-yl}propanoic acid 
• 1373762-77-6 7-({5-[(3,5-bis-triflouromethylphenyl)-2-oxoethylsulfanyl]-1,3,4-oxadiazol-2-yl}methoxy)-4-methylchromen-2-one 
• 1375797-62-8 1-(3,5-bis(trifluoromethyl)phenyl)-2-(1H-benzo[d][1,2,3]triazol-1-yl)ethanone 

Relevant articles and documents

Synthesis and structural elucidation of novel 2,4-Disubstituted 1,3-Oxazole analogues for pharmacological properties

A series of novel 2,4-disubstituted 1,3-oxazole analogues (3a-i) has been designed and synthesized between 1-[3,5-bis(trifluoromethyl)-phenyl]-2-bromoethan-1-one and substituted amides by microwave assisted method. 2,4-Disubstituted 1,3-oxazole analogues

Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments

Targeted covalent inhibition and the use of irreversible chemical probes are important strategies in chemical biology and drug discovery. To date, the availability and reactivity of cysteine residues amenable for covalent targeting have been evaluated by proteomic and computational tools. Herein, we present a toolbox of fragments containing a 3,5-bis(trifluoromethyl)phenyl core that was equipped with chemically diverse electrophilic warheads showing a range of reactivities. We characterized the library members for their reactivity, aqueous stability and specificity for nucleophilic amino acids. By screening this library against a set of enzymes amenable for covalent inhibition, we showed that this approach experimentally characterized the accessibility and reactivity of targeted cysteines. Interesting covalent fragment hits were obtained for all investigated cysteine-containing enzymes.

An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases

Targeted covalent inhibitors represent a viable strategy to block protein kinases involved in different disease pathologies. Although a number of computational protocols have been published for identifying druggable cysteines, experimental approaches are limited for mapping the reactivity and accessibility of these residues. Here, we present a ligand based approach using a toolbox of fragment-sized molecules with identical scaffold but equipped with diverse covalent warheads. Our library represents a unique opportunity for the efficient integration of warhead-optimization and target-validation into the covalent drug development process. Screening this probe kit against multiple kinases could experimentally characterize the accessibility and reactivity of the targeted cysteines and helped to identify suitable warheads for designed covalent inhibitors. The usefulness of this approach has been confirmed retrospectively on Janus kinase 3 (JAK3). Furthermore, representing a prospective validation, we identified Maternal embryonic leucine zipper kinase (MELK), as a tractable covalent target. Covalently labelling and biochemical inhibition of MELK would suggest an alternative covalent strategy for MELK inhibitor programs.

Comparative reactivity analysis of small-molecule thiol surrogates

Targeted covalent inhibitors represent an increasingly popular approach to modulate challenging drug targets. Since covalent and non-covalent interactions are both contributing to the affinity of these compounds, evaluation of their reactivity is a key-step to find feasible warheads. There are well-established HPLC- and NMR-based kinetic assays to tackle this task, however, they use a variety of cysteine-surrogates including cysteamine, cysteine or acetyl-cysteine and GSH. The diverse nature of the thiol sources often makes the results incomparable that prevents compiling a comprehensive knowledge base for the design of covalent inhibitors. To evaluate kinetic measurements from different sources we performed a comparative analysis of the different thiol surrogates against a designed set of electrophilic fragments equipped with a range of warheads. Our study included seven different thiol models and 13 warheads resulting in a reactivity matrix analysed thoroughly. We found that the reactivity profile might be significantly different for various thiol models. Comparing the different warheads, we concluded that – in addition to its human relevance - glutathione (GSH) provided the best estimate of reactivity with highest number of true positives identified.

HETEROCYCLIC COMPOUND

Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formu

AgF/TFA-promoted highly efficient synthesis of α-haloketones from haloalkynes

A AgF/TFA-promoted highly efficient synthesis of a wide range of α-haloketones from haloalkynes is described. The reactions are conducted under convenient conditions and provide products in moderate to excellent yields, with broad substrate scope, including a variety of aromatic chloroalkynes and bromoalkynes.

DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES

The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS

The invention relates to compounds of formula I wherein R1 to R9 have the designations cited in the patent claims. Medicaments containing this type of compound can be used in the prevention or treatment of various illnesses. Said compounds can be used, inter alia, for renal diseases such as acute or chronic kidney failure, for disturbances of the biliary function, for respiratory disturbances such as snoring or sleep apnoea, or for apoplexy.

Compounds and compositons for treating C1s-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.

Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors

The present invention is directed to compounds of Formula I: wherein X is O, S or NR7and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.